Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 197 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resistant Hypertension Clear all
Terminated Not applicable Interventional

Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp)

NCT00477477
View directory record Official record
Conditions
Childhood Obesity, Dyslipidemia, Insulin Resistance, Hypertension
Interventions
Diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 22, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

NCT05562934
View directory record Official record
Conditions
Resistant Hypertension
Interventions
XXB750 drug, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Anniston, Alabama • Birmingham, Alabama • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 22, 2026, 2:12 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Physical Inactivity and Insulin Resistance in Skeletal Muscle.

NCT00536211
View directory record Official record
Conditions
Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
Interventions
Exercise, Metformin
Behavioral · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
20 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 22, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

NCT05769608
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
104
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

NCT05888233
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Interventions
Allopurinol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 22, 2026, 2:12 AM EDT
Active, not recruiting Not applicable Interventional Results available

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426
View directory record Official record
Conditions
Hypertension, Vascular Diseases
Interventions
The Paradise® Renal Denervation Ultrasound System, Sham Procedure
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 22, 2026, 2:12 AM EDT
Completed Not applicable Interventional

Project WHADE: A Partner-Based Physical Activity Program for Women

NCT06350604
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes, Metabolic Syndrome, Smoking, High Cholesterol, PreDiabetes, Prehypertension
Interventions
Project WHADE: A Partner-Based Physical Activity Program for Women
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Glassboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 22, 2026, 2:12 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 22, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Results available

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

NCT03273257
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Riociguat, Placebo, Pulmonary endarterectomy
Drug · Procedure
Lead sponsor
International CTEPH Association
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 22, 2026, 2:12 AM EDT
Recruiting No phase listed Observational

Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia

NCT06802861
View directory record Official record
Conditions
Preeclampsia, Preeclampsia (PE), Preeclampsia (PE) Risk, Obesity and Obesity-related Medical Conditions, Pregnancy, Pregnancy Complications, Gestational Diabetes, Gestational Diabetes Mellitus in Pregnancy, Gestational Complications
Interventions
Not listed
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 22, 2026, 2:12 AM EDT
Recruiting Not applicable Interventional

Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients

NCT06049420
View directory record Official record
Conditions
Obesity, Hyperlipidemias, Polycystic Ovary Syndrome, Hypertension, Coronary Heart Disease, Heart Failure, Depression, Anxiety, Type II Diabetes, Metabolic Syndrome
Interventions
Lifestyle counseling and coaching
Behavioral
Lead sponsor
West Virginia School of Osteopathic Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lewisburg, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 22, 2026, 2:12 AM EDT
Completed Phase 1 Interventional

Effects of Dark Chocolate on Insulin Sensitivity in People With High Blood Pressure

NCT00099476
View directory record Official record
Conditions
Hypertension
Interventions
Effects of dark chocolate
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 2:12 AM EDT
Withdrawn Not applicable Interventional

Role of Enhanced External Counterpulsation (EECP) Therapy in Patients With Resistant Hypertension

NCT00953797
View directory record Official record
Conditions
Hypertension
Interventions
Enhanced External Counterpulsation
Device
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 22, 2026, 2:12 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of How Exercise or Weight Loss Effects Metabolic Syndrome

NCT00292994
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance, Obesity
Interventions
Exercise, Weight Loss
Behavioral
Lead sponsor
Yankton Clinical Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Yankton, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2006 · Synced Oct 22, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

NCT00666172
View directory record Official record
Conditions
Atherosclerosis, Diabetes Mellitus, Obesity, Dyslipidemia, Hypertension
Interventions
Exercise, Weight Loss
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Results available

Insulin Resistance in Pulmonary Arterial Hypertension

NCT00825266
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
bosentan, Pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 22, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524
View directory record Official record
Conditions
PAH
Interventions
75mg CXA-10, 150mg CXA-10, Placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 22, 2026, 2:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes

NCT00005760
View directory record Official record
Conditions
Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 2:12 AM EDT
Active, not recruiting Not applicable Interventional

Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women

NCT06360536
View directory record Official record
Conditions
Overweight or Obesity, Prediabetes or Diabetes, Prehypertension (Elevated Blood Pressure) or Hypertension, Resistance Training
Interventions
Resistance Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 64 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 2:12 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

NCT01271374
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan, losartan and HCTZ
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 22, 2026, 2:12 AM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 2:12 AM EDT
Completed Not applicable Interventional

12 Weeks of Resistance Band Exercise Impacts on Metabolic Syndrome Progression in Postmenopausal Women

NCT04014686
View directory record Official record
Conditions
Metabolic Syndrome, Dyslipidemias, Insulin Resistance, Hypertension
Interventions
No exercise intervention group, Resistance band exercise intervention group
Other · Behavioral
Lead sponsor
Pusan National University
Other
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 22, 2026, 2:12 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

NCT00185705
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Dyslipidemia
Interventions
Telmisartan
Drug
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 22, 2026, 2:12 AM EDT
Recruiting Phase 2 Interventional

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

NCT06343298
View directory record Official record
Conditions
Difficult to Control Hypertension
Interventions
MANP, Placebo Matched control
Drug · Other
Lead sponsor
E-Star BioTech, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
23
States / cities
Little Rock, Arkansas • Lake Forest, California • Westlake Village, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 22, 2026, 2:12 AM EDT